Two lab technicians in safety glasses testing medical-device equipment, one at a computer and one adjusting an instrument rack

Medical & regulated devices

MDS2 explained: what the Manufacturer Disclosure Statement for Medical Device Security actually covers

Last updated:

MDS2 (Manufacturer Disclosure Statement for Medical Device Security) is the standardized, 23-category form medical device manufacturers complete so hospitals and health systems can assess a device's security controls before procurement — a HIMSS/NEMA standard now in its ANSI/NEMA HN 1-2019 edition, recognized by FDA as a consensus standard but, by FDA's own account, not a substitute for the cybersecurity evidence Section 524B of the FD&C Act otherwise requires. Used well, it replaces dozens of vendor-specific security questionnaires with one comparable format; used as a checkbox, it is only as reliable as whoever in the manufacturer's organization filled it in.

FDA's recognized-consensus-standard entry is drawn directly from accessdata.fda.gov. ANSI/NEMA HN 1-2019 itself is a paid standard (available from ANSI, NEMA, Intertek and other standards resellers, with a no-cost copy also distributed via AAMI). The category names, question IDs and question wording on this page are taken from the MDS2 worksheet NEMA publishes as the standard's Section 5 form, checked on 12 November 2026; the completion instructions are summarized from the standard's published translation.

Key takeaways

  • FDA's recognized-consensus-standard entry is drawn directly from accessdata.fda.gov.
  • Each category holds a set of short, numbered questions rather than a long narrative (the NEMA worksheet heads the SGUD section "Security Guidance").
  • The form is a spreadsheet, not a paper questionnaire.
  • FDA recognizes ANSI/NEMA HN 1-2019 as a consensus standard — recognition number 13-123, recognized 19 December 2022 — meaning a manufacturer can point to conformance with it as part of a security risk assessment.

What is MDS2, and why does it exist?

Before MDS2, a hospital buying an infusion pump, imaging system or patient monitor had no standard way to ask a manufacturer about its security controls — every health system wrote its own questionnaire, and every manufacturer answered a different one. HIMSS and NEMA published the first MDS2 in 2004 to fix that with a single, comparable form; updates followed as HN 1-2008 and HN 1-2013, and the current edition, ANSI/NEMA HN 1-2019, was revised under NEMA's Medical Imaging and Technology Alliance (MITA). It supersedes the 2013 version and runs 36 pages: the form itself, plus instructions for completing it. The intended workflow is straightforward — the manufacturer discloses, once, in a format every hospital's biomedical or IT security team already knows how to read, rather than negotiating a bespoke questionnaire per sale.

What are the 23 MDS2 categories?

Code Category
MPII Management of Personally Identifiable Information
ALOF Automatic Logoff
AUDT Audit Controls
AUTH Authorization
CSUP Cybersecurity Product Upgrades
DIDT Health Data De-Identification
DTBK Data Backup and Disaster Recovery
EMRG Emergency Access
IGAU Health Data Integrity and Authenticity
MLDP Malware Detection/Protection
NAUT Node Authentication
CONN Connectivity Capabilities
PAUT Person Authentication
PLOK Physical Locks
RDMP Roadmap for Third Party Components in Device Life Cycle
SBOM Software Bill of Materials
SAHD System and Application Hardening
SGUD Security Guides
STCF Data Storage Confidentiality
TXCF Transmission Confidentiality
TXIG Transmission Integrity
RMOT Remote Service
OTHR Other Security Considerations

Each category holds a set of short, numbered questions rather than a long narrative (the NEMA worksheet heads the SGUD section "Security Guidance"). Two categories are worth flagging for device makers already building other parts of a security program: SBOM is a direct line item on the form, so a manufacturer already producing a firmware SBOM or hardware BOM is answering this category with existing evidence rather than starting from scratch, and NAUT/PAUT (node and person authentication) are frequently where procurement teams and clinical engineers focus follow-up questions, since weak device-to-device authentication on a hospital network has direct patient-safety implications.

How is the HN 1-2019 form built?

The form is a spreadsheet, not a paper questionnaire. NEMA publishes it as a free MDS2 worksheet, and the standard allows anyone to copy and use that Section 5 form; translations must keep the original section labels. Four rules from the completion instructions, as given in the Japanese translation of HN 1-2019 published by JIRA, shape every answer:

  1. Every question gets "Yes", "No" or "N/A"Where an answer needs context, the manufacturer adds "See Note X" and writes the note.
  2. No section is skippedSections that do not apply are answered "No" or "N/A"; a software-only product marks the physical-only sections "N/A".
  3. Answers can point to other documents, such as an administration guide, but the note should give a short summary and say how to obtain the document.
  4. Each question carries a crosswalkColumns H, I and J map it to IEC TR 80001-2-2:2012, NIST SP 800-53 Rev. 4 and ISO/IEC 27002:2013, so a hospital can file the answer against its own control framework.

The worksheet opens with a device description block of 15 fields (DOC-1 to DOC-11.4): manufacturer, device model, document ID, release date, and three yes/no questions that hospitals read first — DOC-8 (does the manufacturer have a coordinated vulnerability disclosure program for this device?), DOC-9 (is it part of an ISAO?) and DOC-10 (is a network or data flow diagram available?). The instructions also ask for a plain device description, without marketing or trade names. After that block come 225 numbered questions, counting sub-questions:

Questions Categories
30 or more CSUP (34), AUDT (30)
15–22 MPII (22), SAHD (22), CONN (19), PAUT (16), MLDP (15)
4–8 AUTH (8), SBOM (8), STCF (7), DTBK (6), TXCF (6), RMOT (6), SGUD (5), NAUT (4), PLOK (4), RDMP (4)
1–2 ALOF, DIDT, IGAU, TXIG (2 each), EMRG (1)
Free text OTHR (notes only)

Source: NEMA MDS2 worksheet, counted 12 November 2026 (one SAHD question is tagged "SHAD-15" in the sheet and is counted under SAHD).

The 2019 revision added the CONN, RMOT, SBOM and RDMP sections and the OTHR placeholder, and moved remote-service questions out of AUDT into RMOT.

What does MDS2 not prove?

FDA recognizes ANSI/NEMA HN 1-2019 as a consensus standard — recognition number 13-123, recognized 19 December 2022 — meaning a manufacturer can point to conformance with it as part of a security risk assessment. The FDA recognition record gives the scope in one sentence: the information "is intended to assist professionals responsible for executing security risk assessments in their management of medical device security capabilities" and "may be inappropriate for other purposes." It is also explicit that this is not sufficient on its own: conformance to the standard "may not satisfy all cybersecurity requirements" under Section 524B of the FD&C Act, and FDA directs manufacturers to its separate cybersecurity, software and postmarket management guidance for what a submission actually needs. In practice that means MDS2 sits alongside, not in place of, the evidence FDA's premarket cybersecurity guidance expects — a threat model, a vulnerability-management plan, and testing evidence — and alongside an ongoing security risk management file maintained under AAMI SW96, which MDS2 was never designed to replace.

Where does MDS2 fit in FDA and EU MDR files?

Neither regulator requires the form by name, but both name it as a way to deliver security information to the people who run the device.

Document What it says about MDS2 or the information it carries
FDA premarket cybersecurity guidance (3 February 2026), Section VI.A After listing labeling recommendations (network ports, SBOM, update procedures, logging, end of support), it says "a revision-controlled" MDS2 and the Customer Security Documentation in JSP2 "may address a number of the above recommendations."
MDCG 2019-16 rev.1, section 2.6.2 The operator "needs to contact the manufacturer if an appropriate set of security information is not available," naming the MDS2 among the documents that can carry it.
Regulation (EU) 2017/745, Annex I 17.4 and 23.4(ab) Manufacturers must set out, and put in the instructions for use, "minimum requirements concerning hardware, IT networks characteristics and IT security measures, including protection against unauthorised access, necessary to run the software as intended."

Two consequences follow. FDA's wording is "revision-controlled": a form without a document ID and release date (DOC-4, DOC-7) tied to a software version is weak evidence. And for an EU file the MDS2 can support the Annex I 23.4(ab) information, but the instructions for use still have to carry it; MDCG 2019-16 treats the form as one channel, not a substitute for labeling.

Which answers need engineering evidence behind them?

Most hospital follow-up lands on a small set of questions. The question text below is quoted from the NEMA worksheet; the evidence column is SoftWSP's guidance on what to keep on file, not part of the standard.

ID Question (worksheet text, shortened) Evidence to keep
DOC-8 Does the manufacturer have a vulnerability disclosure program for this device? Published policy and intake route; see CVD under ISO/IEC 29147 and 30111
CSUP-11 Does the manufacturer have a process in place to assess device vulnerabilities and updates? Monitoring procedure, triage records per CVE, review cycle (CSUP-11.2)
RDMP-3 Does the manufacturer maintain a web page or other source of information on software support dates and updates? Public support-period page with the same dates as the labeling
RDMP-4 Does the manufacturer have a plan for managing third-party component end-of-life? Component end-of-life list linked to the SBOM
SBOM-1 to SBOM-2.3 Is the SBoM available; does it follow a standard method; are components, suppliers and major versions identified? Machine-readable SBOM per release meeting the minimum elements
SBOM-4 Is there an update process for the SBoM? Release procedure step that regenerates the SBOM
SAHD-3.2 Does the device employ any mechanism … to ensure the software updates are the manufacturer-authorized updates? Update-signing design and the verification test
NAUT-3 Does the device use certificate-based network connection authentication? Certificate provisioning and renewal design
EMRG-1 Does the device incorporate an emergency access (i.e. "break-glass") feature? Design description and how its use is logged

Worked example: how would a hypothetical infusion pump team fill in the SBOM and CSUP rows?

Hypothetical device and values, for illustration only. A maker of a networked bedside infusion pump is answering an MDS2 request for firmware release 4.2.

  1. Fix the document identity firstDOC-4 gets a controlled document number with a revision letter and DOC-7 the release date of firmware 4.2, so the form maps to one build.
  2. Answer SBOM-1 from the build, not from memoryThe team generates an SBOM from the released 4.2 firmware image and answers SBOM-1 "Yes", with a note on how a hospital requests the file.
  3. Answer SBOM-2.1 to 2.3 from the file's fieldsComponent names, suppliers and versions are present, so each is "Yes". The pump has no service command that lists installed components, so SBOM-3 is "No", with a note pointing to the SBOM file instead.
  4. Work through CSUP-3The device contains firmware, so CSUP-3 is "Yes". Updates are installed by vendor-authorized service (CSUP-3.2 "Yes"), and the pump cannot receive remote installation (CSUP-3.3 "No").
  5. Back CSUP-11 with a real processThe note names the sources the team monitors (NVD, the CISA Known Exploited Vulnerabilities catalog, vendor advisories) and the review cycle that answers CSUP-11.2.
  6. Cross-check before releaseAn engineer compares the form with the premarket labeling. If the labeling says field engineers can push updates remotely while CSUP-3.3 says "No", one of the two is wrong and is fixed before the form goes out.
  7. Trigger a new revision on changeFirmware 4.3 adds a Bluetooth module: CONN and the SBOM answers change, so the form gets a new revision and release date.

Why is a completed form not the same as a verified one?

MDS2 is self-reported. Healthcare procurement commentary on using the form in practice describes a specific, recurring failure mode: a form routed through a sales channel can come back incomplete or inaccurate, because the person completing it may not be the engineer who actually knows the product's security posture, and nothing in the standard itself requires independent verification of the answers or sign-off above the sales team. It is also a snapshot — completed at launch or at a point in a product's life, not automatically refreshed when a vulnerability is disclosed or a security control changes. That gap is exactly what an ongoing PSIRT and coordinated vulnerability disclosure process exists to cover: MDS2 tells a hospital what the device was built with, a PSIRT tells them what has changed since.

What are the common pitfalls?

  • One form for a product family. Answers that differ by model or option belong in notes per question; the instructions ask for exactly that.
  • "Yes" without a note on SBOM-1. Hospitals then ask where the SBOM is; say how it is delivered.
  • Unanswered rows. The Yes/No/N/A rule exists so the sheet can be processed automatically; blanks break that and read as evasion.
  • Contradicting the labeling. Ports, remote access and update paths in the MDS2 must match the instructions for use and the premarket labeling.
  • Treating "N/A" as a safe default. CSUP-1 tells the manufacturer to answer the CSUP section "N/A" only when the device has no software or firmware that may need security updates.

Where should a manufacturer start?

  1. Assign MDS2 completion to engineering and security, not salesThe answers in all 23 categories should reflect what the product actually does, drawn from the same evidence base as your SBOM and security risk management file.
  2. Treat SBOM and NAUT/PAUT answers as load-bearingThese are the categories hospital procurement and clinical engineering teams scrutinize most; back them with real artifacts, not a blanket "yes."
  3. Republish when the product's security posture changes materiallyHN 1-2019 sets no mandatory review interval, so build your own trigger — a new firmware release, a disclosed vulnerability, or a support-lifecycle change — into your release process.
  4. For hospitals and integrators: corroborate, don't just collectUse MDS2 to compare devices on a like-for-like basis, then check high-stakes answers against the vendor's published advisories and support commitments before relying on them. Published forms such as this HN 1-2019 MDS2 for a Philips/TOMTEC software product show how much a note adds to a bare "Yes".
  5. Keep MDS2, your SBOM and your FDA submission evidence consistentA mismatch between what the MDS2 form discloses and what a premarket submission or published SBOM shows is the kind of inconsistency a hospital's security review — or an FDA reviewer — is positioned to notice.

SoftWSP covers the SBOM side of that evidence: the platform extracts an SBOM from the device firmware image as CycloneDX 1.6 JSON and matches its components against NVD, CISA KEV, FIRST EPSS and CISA ICS advisories (CSAF), and an AI step drafts a cited report that an engineer reviews. That gives the SBOM rows and the CSUP-11 vulnerability-assessment note something concrete to point to. SoftWSP does not fill in the MDS2 form, and it does not write VEX statements or judge whether a matched vulnerability is reachable; those answers stay with the manufacturer's engineers. See device firmware security for the scope.

This guide is general information, not legal or regulatory advice. Premarket submission questions go to FDA's Division of Medical Device Cybersecurity, the technical contact named on the FDA recognition record.

Put this guide to work

Frequently asked questions

What is MDS2 and who publishes it?

MDS2 (Manufacturer Disclosure Statement for Medical Device Security) is a standardized form medical device manufacturers complete so that healthcare delivery organizations (HDOs) can assess a device's security controls before procurement, without each hospital writing its own vendor security questionnaire. It began in 2004 as a joint effort of the Healthcare Information and Management Systems Society (HIMSS) and the National Electrical Manufacturers Association (NEMA), with updates published as HIMSS/NEMA Standard HN 1-2008 and HN 1-2013. The current edition, ANSI/NEMA HN 1-2019, was revised under the leadership of NEMA's Medical Imaging and Technology Alliance (MITA) and supersedes the 2013 version; it is a 36-page document consisting of the MDS2 form itself plus instructions for completing it.

What does the MDS2 form actually ask about?

The ANSI/NEMA HN 1-2019 form is organized into 23 named security categories, each with its own short code: Management of Personally Identifiable Information (MPII), Automatic Logoff (ALOF), Audit Controls (AUDT), Authorization (AUTH), Cybersecurity Product Upgrades (CSUP), Health Data De-Identification (DIDT), Data Backup and Disaster Recovery (DTBK), Emergency Access (EMRG), Health Data Integrity and Authenticity (IGAU), Malware Detection/Protection (MLDP), Node Authentication (NAUT), Connectivity Capabilities (CONN), Person Authentication (PAUT), Physical Locks (PLOK), Roadmap for Third Party Components in Device Life Cycle (RDMP), Software Bill of Materials (SBOM), System and Application Hardening (SAHD), Security Guides (SGUD), Data Storage Confidentiality (STCF), Transmission Confidentiality (TXCF), Transmission Integrity (TXIG), Remote Service (RMOT) and Other Security Considerations (OTHR). For each, the manufacturer answers whether the control is present, with space for notes — a manufacturer disclosing it ships a [firmware SBOM](/guides/firmware-sbom/) under the SBOM category, for example, is answering one of these 23 categories directly, not a separate requirement.

Does a completed MDS2 mean a device is secure, or satisfy FDA requirements?

No, on both counts. FDA recognizes ANSI/NEMA HN 1-2019 as a consensus standard (recognition number 13-123, recognized 19 December 2022) that can support a manufacturer's security risk assessment, but FDA's own recognition entry states explicitly that conformance to this standard alone may not satisfy all cybersecurity requirements under Section 524B of the FD&C Act, and that manufacturers should also consult FDA's cybersecurity, software and postmarket management guidance documents. MDS2 itself makes a narrower claim: it is a disclosure of which controls a device has, in the manufacturer's own words, not an independent security assessment, a penetration test result, a [security risk management file under AAMI SW96](/guides/aami-sw96-medical-device-security-risk-management/), or a substitute for the evidence [FDA's premarket cybersecurity guidance](/guides/fda-premarket-cybersecurity-medical-devices/) expects in a 510(k) or PMA submission.

What are MDS2's known limitations in practice?

The form is self-reported, and healthcare procurement commentary on using it describes the predictable consequence: forms submitted through a sales channel can come back incomplete or with inaccurate information, because the person filling it out may not be the engineer who knows the product's actual security posture, and there is no independent verification built into the standard itself. It is also a point-in-time snapshot — a form completed at launch does not reflect a vulnerability disclosed two years later, which is why [a published PSIRT and vulnerability disclosure process](/guides/first-psirt-services-framework/) matters alongside it, not instead of it. Procurement guidance commonly recommends getting MDS2 responses attested at a level above the sales team, and treating a completed form as the start of a security conversation with a hospital's biomedical or IT security group, not the end of one.

How should a manufacturer or hospital actually use MDS2 well?

For a manufacturer: assign MDS2 completion to the same team that owns your security risk management file and SBOM, not to sales, so the answers in all 23 categories match what engineering actually knows about the product, and update the form when the product's security posture changes materially — the standard itself does not set a mandatory review interval. For a hospital or integrator: use MDS2 as a structured starting point for comparing devices on a like-for-like basis, but corroborate high-stakes answers — especially NAUT, AUTH, TXCF and SBOM — against the vendor's published security advisories, support-lifecycle commitments and, where available, independent testing, rather than treating a 'yes' on the form as verified fact.

Sources

  1. FDA: Recognized Consensus Standard — ANSI NEMA HN 1-2019, Manufacturer Disclosure Statement for Medical Device Security (recognition number 13-123, recognized 19 December 2022)
  2. AAMI array: "Standards Spotlight: Revised MDS2 Expands Documentation of Security Control Features"
  3. Journal of Healthcare Contracting: "Cybersecurity: Make MDS2 part of the procurement process"
  4. NEMA: Manufacturer Disclosure Statement for Medical Device Security (MDS2) standard listing
  5. NEMA: MDS2 worksheet (ANSI/NEMA HN 1-2019 Section 5 form, xlsx; 15 DOC fields and 225 question IDs counted 12 November 2026)
  6. JIRA: Japanese translation of ANSI/NEMA HN 1-2019 with the completion instructions (Sections 2-5)
  7. FDA: Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (guidance, 3 February 2026), Section VI.A
  8. MDCG 2019-16 rev.1, Guidance on Cybersecurity for medical devices (July 2020), section 2.6.2
  9. Regulation (EU) 2017/745 (MDR), Annex I sections 17.4 and 23.4(ab), EUR-Lex
  10. Philips / TOMTEC: published MDS2 for TOMTEC-ARENA TTA2.50 (example of a completed HN 1-2019 form)
Was this guide helpful?

In this cluster

MDS2 explained: what the Manufacturer Disclosure Statement for Medical Device Security actually covers